NASDAQ:AXSM - Axsome Therapeutics Stock Price, Price Target & More

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics Inc (NASDAQ:AXSM) issued its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.09. View Axsome Therapeutics' Earnings History.

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Axsome Therapeutics.

4 Wall Street analysts have issued 1-year price objectives for Axsome Therapeutics' shares. Their predictions range from $10.00 to $31.00. On average, they anticipate Axsome Therapeutics' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 455.6% from the stock's current price. View Analyst Ratings for Axsome Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Axsome Therapeutics saw a increase in short interest in June. As of June 29th, there was short interest totalling 1,804,508 shares, an increase of 103.1% from the June 15th total of 888,345 shares. Based on an average daily volume of 237,343 shares, the short-interest ratio is currently 7.6 days. Currently, 10.9% of the shares of the company are sold short. View Axsome Therapeutics' Current Options Chain.

Some companies that are related to Axsome Therapeutics include Minerva Neurosciences (NERV), Corvus Pharmaceuticals (CRVS), Avid Bioservices (CDMO), Catalyst Pharmaceuticals (CPRX), Innate Pharma (IPHYF), Corbus Pharmaceuticals (CRBP), Kala Pharmaceuticals (KALA), Kezar Life Sciences (KZR), Tyme Technologies (TYME), Zafgen (ZFGN), Selecta Biosciences (SELB), CELYAD SA/ADR (CYAD), Corium International (CORI), Biofrontera (BFRA) and Athersys (ATHX).

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Media headlines about AXSM stock have trended positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axsome Therapeutics earned a daily sentiment score of 0.39 on Accern's scale. They also assigned media coverage about the company an impact score of 49.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Axsome Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Alethea Capital Management LLC (1.05%). View Institutional Ownership Trends for Axsome Therapeutics.

AXSM stock was acquired by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC. View Insider Buying and Selling for Axsome Therapeutics.

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AXSM stock can currently be purchased for approximately $3.15.

Axsome Therapeutics has a market capitalization of $79.63 million. The company earns $-28,940,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Axsome Therapeutics employs 25 workers across the globe.

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.